Kiniksa Pharmaceuticals International, plc
KNSA
$20.24
-$1.52-6.99%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 122.54M | 112.21M | 108.63M | 79.86M | 83.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.54M | 112.21M | 108.63M | 79.86M | 83.40M |
| Cost of Revenue | 66.09M | 49.42M | 42.34M | 31.38M | 26.52M |
| Gross Profit | 56.45M | 62.80M | 66.30M | 48.47M | 56.87M |
| SG&A Expenses | 40.54M | 46.40M | 42.40M | 38.68M | 36.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 141.84M | 121.87M | 108.75M | 96.40M | 83.31M |
| Operating Income | -19.30M | -9.66M | -117.00K | -16.54M | 81.00K |
| Income Before Tax | -16.98M | -7.20M | 2.30M | -14.28M | 2.45M |
| Income Tax Expenses | -8.09M | 5.49M | 6.21M | 3.43M | -22.79M |
| Earnings from Continuing Operations | -8.89M | -12.69M | -3.91M | -17.70M | 25.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.89M | -12.69M | -3.91M | -17.70M | 25.24M |
| EBIT | -19.30M | -9.66M | -117.00K | -16.54M | 81.00K |
| EBITDA | -18.90M | -9.26M | 313.00K | -16.08M | 621.00K |
| EPS Basic | -0.12 | -0.18 | -0.06 | -0.25 | 0.36 |
| Normalized Basic EPS | -0.15 | -0.06 | 0.02 | -0.13 | 0.02 |
| EPS Diluted | -0.12 | -0.18 | -0.06 | -0.25 | 0.35 |
| Normalized Diluted EPS | -0.15 | -0.06 | 0.02 | -0.13 | 0.02 |
| Average Basic Shares Outstanding | 72.32M | 71.73M | 71.00M | 70.63M | 70.37M |
| Average Diluted Shares Outstanding | 72.32M | 71.73M | 71.00M | 70.63M | 72.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
